Drug Profile

Research programme: transient receptor potential cation channel subfamily A anatgonists - Hydra Biosciences

Alternative Names: HC-030031; Research programme: TRPA1 anatagonist - Hydra Biosciences

Latest Information Update: 02 Jan 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hydra Biosciences
Class Analgesics; Small molecules
Mechanism of Action TRPA1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Asthma; Pain

Most Recent Events

14 Dec 2018 Eli Lilly acquires TRPA1 antagonists programme from Hydra Biosciences
16 Jul 2016 No development reported - Preclinical for Asthma in USA (unspecified route)
16 Jul 2016 No development reported - Preclinical for Pain in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com